Listen: How bad will the pandemic get? Plus: Gilead’s pricing dilemma and fighting Covid-19 in New York
What if the curve just stays flat? How much should a Covid-19 drug cost? And what’s it like on the ground in the epicenter of the novel coronavirus?
We discuss all that and more this week on “The Readout LOUD,” STAT’s biotech podcast. First, STAT’s Sharon Begley joins us to explain what the novel coronavirus may have in store for the U.S. this summer and beyond with a look at some grim statistical models. Then, we examine Gilead Sciences, whose upcoming decision on a price for the Covid-19 drug remdesivir underlines a controversial history of marketing expensive medicines. Finally, we talk to Ethan Weiss, a Bay Area cardiologist who flew to New York City to treat patients at the outbreak’s epicenter.
